Efficacy of Phase 3 Trial of Rts, S/As01 Malaria Vaccine: The Need for an Alternative Development Plan

Efficacy of Phase 3 Trial of Rts, S/As01 Malaria Vaccine: The Need for an Alternative Development Plan Publisher Pubmed

Mahmoudi S^{1, 2} ; Keshavarz H^{2, 3}

Show Affiliations

1. Pediatric Infectious Disease Research Center, Tehran University of Medical Science, Tehran, Iran
2. Center for Research of Endemic Parasites of Iran (CREPI), Tehran University of Medical Sciences, Tehran, Iran
3. Department of Medical Parasitology and Mycology, School of Public Heath, Tehran, University of Medical Science, Tehran, Iran

Source: Human Vaccines and Immunotherapeutics Published:2017

Abstract

Although vaccines would be the ideal tool for control, prevention, elimination, and eradication of many infectious diseases, developing of parasites vaccines such as malaria vaccine is very complex. The most advanced malaria vaccine candidate RTS,S, a pre-erythrocytic vaccine, has been recommended for licensure by EMEA. The results of this phase III trial suggest that this candidate malaria vaccine has relatively little efficacy, and the vaccine apparently will not meet the goal of malaria eradication by itself. Since there are many vaccine candidates in the pipeline1 that are being evaluated in vaccine trials, further study on using of alternative parasite targets and vaccination strategies are highly recommended. © 2017 Taylor & Francis.

2. Computational Study of Quinolone Derivatives to Improve Their Therapeutic Index As Anti-Malaria Agents: Qsar and Qstr, Iranian Journal of Pharmaceutical Research (2015)

Style	Citing Format
MLA	Mahmoudi S, Keshavarz H. "Efficacy of Phase 3 Trial of Rts, S/As01 Malaria Vaccine: The Need for an Alternative Development Plan." Human Vaccines and Immunotherapeutics, vol. 13, no. 9, 2017, pp. 2098-2101.
APA	Mahmoudi S, Keshavarz H (2017). Efficacy of Phase 3 Trial of Rts, S/As01 Malaria Vaccine: The Need for an Alternative Development Plan. Human Vaccines and Immunotherapeutics, 13(9), 2098-2101.
Chicago	Mahmoudi S, Keshavarz H. "Efficacy of Phase 3 Trial of Rts, S/As01 Malaria Vaccine: The Need for an Alternative Development Plan." Human Vaccines and Immunotherapeutics 13, no. 9 (2017): 2098-2101.
Harvard	Mahmoudi S, Keshavarz H (2017) 'Efficacy of Phase 3 Trial of Rts, S/As01 Malaria Vaccine: The Need for an Alternative Development Plan', Human Vaccines and Immunotherapeutics, 13(9), pp. 2098-2101.
Vancouver	Mahmoudi S, Keshavarz H. Efficacy of Phase 3 Trial of Rts, S/As01 Malaria Vaccine: The Need for an Alternative Development Plan. Human Vaccines and Immunotherapeutics. 2017;13(9):2098-2101.
BibTex	@article{ author = {Mahmoudi S and Keshavarz H}, title = {Efficacy of Phase 3 Trial of Rts, S/As01 Malaria Vaccine: The Need for an Alternative Development Plan}, journal = {Human Vaccines and Immunotherapeutics}, volume = {13}, number = {9}, pages = {2098-2101}, year = {2017} }
RIS	TY - JOUR AU - Mahmoudi S AU - Keshavarz H TI - Efficacy of Phase 3 Trial of Rts, S/As01 Malaria Vaccine: The Need for an Alternative Development Plan JO - Human Vaccines and Immunotherapeutics VL - 13 IS - 9 SP - 2098 EP - 2101 PY - 2017 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract